Dr. Agarwal's Health Care Limited share price
NSE: AGARWALEYE · ISIN INE943P01029
Key numbers
- Market cap
- ₹ 15,851 Cr
- Current price
- ₹ 500.00
- 52-week high / low
- ₹ 568 / 401
- Stock P/E
- 107.5
- Book value
- ₹ 63.9
- Dividend yield
- 0.00%
- ROCE
- 11.5%
- ROE
- 6.8%
- Debt to equity
- 0.53
- Sales growth (3 yrs)
- 26.9%
- Profit growth (3 yrs)
- 12.3%
- 1-year return
- 9.9%
About Dr. Agarwal's Health Care Limited
Dr. Agarwal's Health Care Limited engages in running, owning, and managing eye care hospitals, opticals, pharmacies, etc. and related services in India and internationally. It offers femto cataracts, lenticular procedure, retinal surgeries, anterior segment reconstruction, and corneal transplants, as well as refractive and other surgeries. The company also develops, designs, manufactures, imports, and exports healthcare devices, which include ophthalmic diagnostic devices, such as auto perimeter, optical biometers, and ophthalmoscopes. In addition, the company offers consultations, diagnoses, and non-surgical treatments; and sells opticals, contact lenses and accessories, and eye care related pharmaceutical products. Dr. Agarwal's Health Care Limited was incorporated in 2010 and is based in Chennai, India.
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 460 | 487 | 530 | 564 | 614 |
| Operating profit | 131 | 128 | 144 | 161 | 170 |
| Net profit | 33 | 30 | 34 | 40 | 45 |
| EPS (₹) | 1.04 | 0.95 | 1.07 | 1.25 | 1.43 |
Concall summary (2026-08-07)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- For Q1 FY27, total income stood at INR620 crores, up 24% year-on-year, while revenue from operations grew a whopping 26% to INR614 crores.
- Since FY23, we have added 166 new greenfield facilities, accelerating our expansion from 10 facility additions in FY23 to just 18 additions in FY27 alone, which is in this quarter of FY27 alone.
Growth & demand
- Volumes for cataract surgeries grew 16.5% year-on-year, while other surgeries on a blended basis recorded a growth of 13.3%.
- So, overall, on the SSSG front, if I were to breakdown the volume and value, volume grew by around 8% and value grew by around 8%.
Margins & costs
- T he quarter delivered a robust Ind AS EBITDA of INR177 crores, growing 25.2% year -on-year with margins of 28.5%, an improvement of 30 basis points with a PAT margin expanding by 127 basis points to 8.9% despite rising greenfield losses driven by 23 surgical new facilities launched in the 6 months.
- Doctor and employee costs have increased slightly to 34% of total revenues in Q1 FY '27 with the addition of talent across all facilities launched in Q1 FY '27 .
Capex & expansion
- For the quarter ended June 30, 2026, we expanded our footprint by commissioning 18 new greenfield facilities, strengthening our reach and capaci ty.
- For the first qu arter, we have paid close to INR25 crores as far as the acquisition liabilities go.
Risks & challenges
- Corneal transplant come with two inherent challenges.
Peers in Medical Instruments & Supplies
Data for information only, not investment advice. Prices end of day.